Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Research ArticleThe State of the Art

Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging

Christian Schmidkonz, Torsten Kuwert, Armin Atzinger, Michael Cordes, Georg Schett, Andreas Ramming and Theresa Götz
Journal of Nuclear Medicine December 2022, 63 (12) 1786-1792; DOI: https://doi.org/10.2967/jnumed.122.264205
Christian Schmidkonz
1Department of Nuclear Medicine, Friedrich–Alexander University Erlangen–Nürnberg and University Hospital Erlangen, Erlangen, Germany;
2Institute for Medical Engineering, Technical University of Applied Sciences Amberg–Weiden, Weiden, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Torsten Kuwert
1Department of Nuclear Medicine, Friedrich–Alexander University Erlangen–Nürnberg and University Hospital Erlangen, Erlangen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Armin Atzinger
1Department of Nuclear Medicine, Friedrich–Alexander University Erlangen–Nürnberg and University Hospital Erlangen, Erlangen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Cordes
1Department of Nuclear Medicine, Friedrich–Alexander University Erlangen–Nürnberg and University Hospital Erlangen, Erlangen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georg Schett
3Rheumatology and Immunology, Department of Internal Medicine 3, Friedrich–Alexander University Erlangen–Nürnberg and University Hospital Erlangen, Erlangen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Ramming
3Rheumatology and Immunology, Department of Internal Medicine 3, Friedrich–Alexander University Erlangen–Nürnberg and University Hospital Erlangen, Erlangen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theresa Götz
2Institute for Medical Engineering, Technical University of Applied Sciences Amberg–Weiden, Weiden, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Fibroblast activation protein-α (FAP-α) is a type II transmembrane glycoprotein that is overexpressed in activated fibroblasts such as those in the stroma of tumors or in the fibrotic processes accompanying various benign diseases. The recent development and clinical implementation of radiolabeled quinolone-based tracers suitable for PET that act as FAP inhibitors (FAPIs) have opened a new perspective in molecular imaging. Although multiple studies have investigated the use of FAPI imaging in cancer, evidence concerning its use in nonmalignant diseases is still scarce. Herein, we provide a comprehensive review of FAPI imaging in nonmalignant diseases to clarify the current and potential role of this class of molecules in nuclear medicine.

  • fibroblast activation protein
  • inflammatory diseases
  • PET
  • molecular imaging
  • fibrosis

Footnotes

  • Published online Sep. 15, 2022.

  • © 2022 by the Society of Nuclear Medicine and Molecular Imaging.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 63 (12)
Journal of Nuclear Medicine
Vol. 63, Issue 12
December 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging
Christian Schmidkonz, Torsten Kuwert, Armin Atzinger, Michael Cordes, Georg Schett, Andreas Ramming, Theresa Götz
Journal of Nuclear Medicine Dec 2022, 63 (12) 1786-1792; DOI: 10.2967/jnumed.122.264205

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging
Christian Schmidkonz, Torsten Kuwert, Armin Atzinger, Michael Cordes, Georg Schett, Andreas Ramming, Theresa Götz
Journal of Nuclear Medicine Dec 2022, 63 (12) 1786-1792; DOI: 10.2967/jnumed.122.264205
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • FAPI IMAGING IN IgG4-RD
    • FAPI IMAGING IN PULMONARY FIBROSIS (PF)
    • FAPI IMAGING IN CARDIOVASCULAR DISEASES
    • FAPI IMAGING IN BENIGN LESIONS ENCOUNTERED IN ONCOLOGIC IMAGING
    • FAPI IMAGING IN RHEUMATOID ARTHRITIS
    • FAPI IMAGING IN RENAL FIBROSIS
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Artificial Intelligence in Nuclear Medicine: Opportunities, Challenges, and Responsibilities Toward a Trustworthy Ecosystem
  • Imaging Biomarkers for Central Nervous System Drug Development and Future Clinical Utility: Lessons from Neurodegenerative Disorders
Show more The State of the Art

Similar Articles

Keywords

  • fibroblast activation protein
  • inflammatory diseases
  • PET
  • molecular imaging
  • fibrosis
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire